XDXieping Dong

Xieping Dong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xieping Dong has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Jiaxin Chen

    JXHC Key Laboratory of Digital Orthopedics, Nanchang Key Laboratory of Medical 3D Printing Innovation and Translation, Department of Orthopedics, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China

    2 shared publications
  • Xiaofan Chen

    JXHC Key Laboratory of Digital Orthopedics, Nanchang Key Laboratory of Medical 3D Printing Innovation and Translation, Department of Orthopedics, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China

    2 shared publications
  • Yifeng Jiang

    Jiangxi University of Chinese Medicine, Nanchang, China

    2 shared publications
  • Yu Zeng

    Jiangxi University of Chinese Medicine, Nanchang, China

    2 shared publications
  • Feng Wang

    Department of Animal Zoology, Kunming Medical University, Kunming, Yunnan, China

    1 shared publication
  • Haifu Sun

    Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou 215006, China

    1 shared publication

Latest Publications

  • Open Access

    A comparative meta-analysis of stress shielding between short-stem and conventional femoral stem in total hip arthroplasty

    by Yifeng Jiang, Xingyu Wang, Yuanqi Hong, Haocong Chen, Zhe Wang, Yu Zeng, Jiaxin Chen, Xiaofan Chen, Wen Wan, Xieping Dong

    Stress shielding-related complications remain a key clinical challenge in total hip arthroplasty (THA). While short-stem prostheses have shown potential bo


  • Open Access

    Smart immunomodulatory polysaccharide hydrogels promote diabetic bone regeneration by regulating the inflammation-angiogenesis-osteogenesis axis

    by Nanning Lv, Haifu Sun, Xiaofan Chen, He Dong, Wenxiang Tang, Yifeng Jiang, Lihui Hong, Hongye Li, Yusen Qiao, Xieping Dong, et al.


  • Open Access

    Uncovering metabolite-immune interactions in the pathogenesis of psoriatic arthritis: A 2-sample Mendelian randomization study

    by Shuai Chen, Yudong Gan, Yan Jin, Xieping Dong, Feng Wang, Zhongxiong Msc Wu, Zenghui Msc Liu, Zhongzi Zhang

    PsA is a chronic inflammatory joint condition associated with psoriasis, and its underlying mechanisms are not fully elucidated. Serum metabolites, as direct reflections of metabolic status, may influence disease progression by regulating immune cell function; however, the causal relationships and specific pathways require further investigation. The present investigation utilized a 2-sample bidirectional MR methodology, leveraging extensive pooled GWAS data to thoroughly evaluate the causal relationships between 1440 serum metabolites and PsA. Additionally, mediation MR analysis was performed to explore the possible mediating effects of 731 immune cell characteristics. In the primary analysis, inverse-variance weighted was employed, and this was further supported by various sensitivity analyses to confirm the reliability of the findings. The genetic method to infer causality analysis revealed significant positive causal associations between 10 serum metabolites and PsA risk, with quinolinate levels demonstrating the most significant correlation (OR = 1.56, 95% CI: 1.26–1.93); while 4 metabolites (e.g., citrate levels, OR = 0.74, 95% CI: 0.61–0.89) exhibited protective effects. Regarding immune cells, 6 cellular features (e.g., CD20 on B cells) were positively correlated with disease risk, whereas 5 features (primarily HLA-DR expression on monocyte subsets) showed negative correlations. Mediation analysis identified 3 significant pathways,the percentage of the effect explained by the mediator: N6,N6,N6-trimethyllysine levels mediated via B cells (CD20 on IgD+ CD38br), with a proportion of 33.2%; 1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels mediated through monocytes (HLA-DR on CD14− CD16−) with a 32.0% proportion; the unknown metabolite X-24736 also mediated 42.1% of the protective effect via the same monocyte phenotype. This study revealed that elevated amino acid-related metabolites and glycerophospholipids significantly increase PsA risk through immune cell effects. These are closely associated with PsA pathogenesis and may serve as potential biomarkers. The novel findings underscore metabolic-immune interactions as targets for biomarkers and therapies in PsA, advancing personalized medicine.

  • Open Access

    AGPAT3 Regulates Immune Microenvironment in Osteosarcoma via Lysophosphatidic Acid Metabolism

    by Shenghui Su, Yu Zeng, Jiaxin Chen, Xieping Dong

    Background: Recent studies have shown glycerolipid metabolism played an essential role in multiple tumors, however, its function in osteosarcoma is unclear. This study aimed to explore the role of glycerolipid metabolism in osteosarcoma. Methods: We conducted bioinformatics analysis using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database and single-cell RNA sequencing. Least Absolute Shrinkage and Selection Operator (LASSO) regression was used to identify the Glycerolipid metabolism-related genes associated with the clinical outcome of osteosarcoma. Tumor-associated macrophages (TAMs) and their interactions with immune cells were examined through single-cell analysis and co-culture experiments. Virtual screening was employed to identify the potential lysophosphatidic acid receptor 6 (LPAR6) inhibitors. Results: Glycerolipid metabolism-related genes 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3) and aldehyde dehydrogenase 7 family member A1 (ALDH7A1) were identified as key prognostic genes in osteosarcoma, with high AGPAT3 expression correlating with improved survival. Single-cell analysis revealed that AGPAT3 expression is associated with tumor immune microenvironment, particularly with TAMs. Knockdown of AGPAT3 in osteosarcoma cells resulted in elevated lysophosphatidic acid (LPA) levels, which regulated the immune environment, inhibiting cytotoxic T cell function through TAMs’ LPAR6 signaling. LPAR6 signaling in TAMs mediates immune regulation through cytokine secretion, including interleukin-6 (IL-6) and interleukin-10 (IL-10). Further drug virtual screening identified Dutasteride as a potential inhibitor of LPAR6. Conclusion: AGPAT3 is an important gene related to the prognosis of osteosarcoma. Its ability to modulate LPA signaling and TAM activity offers promising therapeutic opportunities for improving osteosarcoma treatment, particularly in immunotherapy contexts.